CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association Scientific Sessions 2026
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel in Autoimmune Disease at the American College of Rheumatology Convergence 2026
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
